Investor Relations

About Vivani

Operating under our Biopharm Division and Neuromodulation Division, Vivani develops, manufactures, and markets therapies that target chronic conditions with high unmet medical needs. 

Our Biopharm Division develops novel, miniature drug implants by leveraging our proprietary NanoPortal™ implant technology for delivering medication steadily over extended periods of time. Our differentiated, drug implant candidates have the potential to ensure patients consistently receive the right dose while potentially avoiding safety concerns that may be associated with fluctuating delivery. 

Our Neuromodulation Division seeks to identify and assess strategic options for advancing prosthetic eye implant candidates. Our primary focus is developing Orion II – a Visual Cortical Prosthesis System created to bring artificial vision to individuals who  are blind due to a wide range of causes.

Latest Presentation

2023 Investor Presentation

Latest Financial Results

Q3 2022

Quarter Ended September 30, 2022

Latest Annual Filing

For Fiscal Year Ending December 31, 2021

Stock Snapshot

IR Contacts


Vivani Medical, Inc.
5858 Horton Street #280
Emeryville, CA 94608
United States
T: 818-833-5000

Investor Relations

Brigid Makes
Chief Financial Officer
T: 818-833-5000

Transfer Agent

Vstock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436